Compare OPLN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPLN | ARQT |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | 4800 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.5B |
| IPO Year | N/A | 2020 |
| Metric | OPLN | ARQT |
|---|---|---|
| Price | $41.01 | $27.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $32.00 | ★ $34.00 |
| AVG Volume (30 Days) | 860.5K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $9.43 | $34.85 |
| Revenue Next Year | $6.80 | $29.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $25.81 | $13.70 |
| 52 Week High | $42.47 | $31.77 |
| Indicator | OPLN | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 61.20 |
| Support Level | $36.17 | $27.63 |
| Resistance Level | $42.47 | $27.79 |
| Average True Range (ATR) | 1.31 | 1.24 |
| MACD | -0.17 | -0.08 |
| Stochastic Oscillator | 54.66 | 54.25 |
Openlane Inc provides a digital marketplace for used vehicles, connecting sellers and buyers in North America and Europe for fast and transparent transactions. Its services include financing, repossessions, repairs, transportation, warranty, and inventory management. The company operates used-vehicle auctions and has two main segments: Marketplace and Finance, with majority revenue coming from the Marketplace segment, which to used vehicle remarketing, including marketplace services, remarketing, or make ready services and all are interrelated, synergistic elements along the auto remarketing chain. The Finance segment, through AFC engaged in business of providing short-term, inventory-secured financing to independent vehicle dealers.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.